New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ABBV;ABT;ALJ;ALDW;FB;WGP;WES;LRCX;WHF From The Last 14 Days
Check below for free stories on ABBV;ABT;ALJ;ALDW;FB;WGP;WES;LRCX;WHF the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
April 15, 2014
14:14 EDTABTEarnings Preview: Abbott's established pharmaceuticals sales in focus
Subscribe for More Information
13:19 EDTFBFacebook volatility increases on sharp sell off into Q1
Subscribe for More Information
13:03 EDTFBFacebook drops sharply on heavy volume, levels to watch
The stock is down 5% to $55.94, heading for a test of support at the $55 area. This was previously a zone of both support and resistance earlier in the year before shares took off to the life high at $72.59. A break below $55 would be bearish, with next major support at $53.55. Resistance is at $56.95.
10:00 EDTWGPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:22 EDTABBVAbbVie initiates Phase III clinical trial of veliparib in lung cancer
AbbVie announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib or ABT-888, in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer. The trial will compare patients randomized to receive either the standard chemotherapies of carboplatin and paclitaxel with the addition of veliparib, versus patients receiving carboplatin and paclitaxel with the addition of placebo. The trial will recruit approximately 900 patients.
08:50 EDTWGPWestern Gas Equity downgraded to Accumulate from Buy at Tudor Pickering
Subscribe for More Information
08:08 EDTFBJDSU appoints Facebook Chief Information Officer Tim Campos to board
JDSU (JDSU) announced that Tim Campos has been appointed to its board, effective April 15. Campos is currently the Chief Information Officer and a member of the senior management team at Facebook (FB).
April 14, 2014
17:31 EDTABBVAbbVie stock could reach $55, Barron's says
Subscribe for More Information
14:06 EDTFBGoogle to acquire Titan Aerospace, WSJ says
Subscribe for More Information
12:26 EDTFBOn The Fly: Midday Wrap
Subscribe for More Information
10:58 EDTFBFacebook entering China a matter of when, not if, says Topeka
Subscribe for More Information
09:36 EDTFBActive equity options trading on open
Subscribe for More Information
09:05 EDTABTAbbott announces FDA clearance for test to diagnose diabetes
Subscribe for More Information
08:59 EDTFBOn The Fly: Pre-market Movers
Subscribe for More Information
07:45 EDTABBVAbbVie defended at BMO Capital
Subscribe for More Information
06:35 EDTFBFacebook looks to provide financial services for users, Financial Times reports
Subscribe for More Information
April 12, 2014
19:23 EDTABBVEnanta reports detailed results from Turquoise ll study
Enanta Pharmaceuticals (ENTA) announced that detailed results from AbbVie’s (ABBV) pivotal phase 3 TURQUOISE-II study, will be presented as a late-breaking oral presentation at the International Liver Congress, ILC, which is the 49th Annual Meeting of the European Association for the Study of the Liver, EASL. Results from the TURQUOISE-II study were featured in the ILC press conference and were published on-line in the New England Journal of Medicine. The TURQUOISE-II study reports results from AbbVie’s investigational three direct-acting antiviral regimen containing ABT-450, Enanta’s lead protease inhibitor discovered through Enanta’s collaboration with AbbVie. The regimen consists of boosted protease inhibitor ABT-450/ritonavir, NS5A inhibitor ABT-267, and non-nucleoside polymerase inhibitor ABT-333. TURQUOISE-II is a global, multi-center, randomized, open-label study evaluating the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie's three direct-acting antiviral regimen with ribavirin, RBV, in adult patients with genotype 1, GT1, chronic hepatitis C virus, HCV, infection with compensated liver cirrhosis. Patients achieved sustained virologic response rates 12 weeks post-treatment, SVR12, of 91.8% and 95.9% in the 12-week and 24-week treatment arms, respectively. Patients in the study were either new to therapy or treatment-experienced, failed previous treatment with pegylated interferon and RBV.
April 11, 2014
12:42 EDTLRCXOn The Fly: Analyst Initiation Summary
ASML (ASML) initiated with a Cautious at ISI Group... Analog Devices (ADI) initiated with a Buy at ISI Group... Applied Materials (AMAT) initiated with a Strong Buy at ISI Group... Aruba Networks (ARUN) initiated with a Buy at SunTrust... Broadcom (BRCM) initiated with a Neutral at ISI Group... CSX (CSX) initiated with an Outperform at Macquarie... Cisco (CSCO) initiated with a Buy at SunTrust... F5 Networks (FFIV) initiated with a Neutral at SunTrust... Genesee & Wyoming (GWR) initiated with a Neutral at Macquarie... Intel (INTC) initiated with a Neutral at ISI Group... Juniper (JNPR) initiated with a Buy at SunTrust... KLA-Tencor (KLAC) initiated with a Neutral at ISI Group... Lam Research (LRCX) initiated with a Strong Buy at ISI Group... Linear Technology (LLTC) initiated with a Cautious at ISI Group... Maxim Integrated (MXIM) initiated with a Neutral at ISI Group... Micron (MU) initiated with a Strong Buy at ISI Group... NVIDIA (NVDA) initiated with a Neutral at ISI Group... NXP Semiconductors (NXPI) initiated with a Strong Buy at ISI Group... Qualcomm (QCOM) initiated with a Strong Buy at ISI Group... Riverbed (RVBD) initiated with a Neutral at SunTrust... SanDisk (SNDK) initiated with a Neutral at ISI Group... Teradyne (TER) initiated with a Buy at ISI Group... Texas Instruments (TXN) initiated with a Neutral at ISI Group... Trulia (TRLA) initiated with a Neutral at Susquehanna... Union Pacific (UNP) initiated with a Neutral at Macquarie... Zillow (Z) initiated with a Positive at Susquehanna... Flamel Technologies (FLML) initiated with a Buy at Roth Capital... Parker Drilling (PKD) initiated with an Accumulate at Tudor Pickering.
09:55 EDTFBFacebook bounces from early low, levels to watch
Shares began at depressed levels this morning, hitting a low of $57.31. That press down was quickly bought, with shares last at $59.62. At that price, next resistance is at $60.39. Support is at $58.51.
09:37 EDTFBActive equity options trading on open
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use